Pharvaris (PHVS) to Release Earnings on Tuesday

Pharvaris (NASDAQ:PHVS) is anticipated to announce its Q4 2025 results before the market opens on Tuesday, April 14th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, April 9, 2026 at 12:30 PM ET.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $28.37 on Tuesday. The business’s 50 day simple moving average is $27.07 and its two-hundred day simple moving average is $25.47. The firm has a market cap of $1.54 billion, a P/E ratio of -8.42 and a beta of -2.58. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.85.

Analyst Ratings Changes

Several research analysts have issued reports on PHVS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Thursday, January 22nd. Wall Street Zen lowered Pharvaris from a “hold” rating to a “sell” rating in a report on Sunday. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Royal Bank Of Canada cut their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average target price of $41.60.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PHVS. Geode Capital Management LLC lifted its holdings in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Amundi lifted its holdings in shares of Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after purchasing an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after purchasing an additional 7,879 shares in the last quarter.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.